=====TURNAROUND CHANCE=====BIOTECH WERT UNTER CASH NOTIERT!!!!! - 500 Beiträge pro Seite

[scopus]

INHIBITEX INC

(INHX)


Klarer kauf

[Richy]

Warum? Wo siehst du das Kursziel?

[scopus]

kurzfristig 2,50$

längerfristig
über 4$

[scopus]

[bioperformer]

Antwort auf Beitrag Nr.: 21.389.416 von scopus am 01.05.06 14:34:57

...sorry, daß ich jetzt hier diesen Q1-Bericht einstelle, aber Zahlen wie auch der Ausblick sind bei weitem besser ausgefallen als von allen erwartet...



Press Release Source: Inhibitex, Inc.


Inhibitex, Inc. Reports First Quarter 2006 Financial Results
Friday May 5, 7:00 am ET
- FDA Clears Initiation of Next Aurexis(R) Clinical Trial -
- Financial Guidance Provided on Reduced Operating Expenses for 2006 -


ATLANTA, May 5 /PRNewswire-FirstCall/ -- Inhibitex, Inc. (Nasdaq: INHX - News) today announced its financial results for the first quarter ended March 31, 2006 and provided financial guidance for the remainder of 2006. The company also reported that it has received authorization from the U.S. Food and Drug Administration (FDA) to initiate a safety and pharmacokinetic trial of Aurexis®, in combination with antibiotics, in 16 patients with confirmed Staphylococcus aureus (S. aureus) bloodstream infections. The company anticipates initiating this trial during the third quarter of 2006.
ADVERTISEMENT


The company also announced that, based on the changes it has recently implemented to reduce and control its costs and expenditures, it currently estimates its net cash burn rate will approximate $10.0 to $11.0 million during the second quarter of 2006, and will decrease to approximately $5.0 to $6.0 million per quarter during the second half of the year.

"Over the past month we have initiated a number of cost reduction and strategic measures that better align our operations with our planned level of research and clinical development activities," stated William D. Johnston, Ph.D., president and chief executive officer of Inhibitex. "As a result, our burn rate has been substantially decreased and our financial position remains very sound. While we anticipate expending additional resources to advance our MSCRAMM®-based clinical and preclinical programs, we are also considering other strategic pathways by which to create shareholder value."

First Quarter 2006 Financial Results

On March 31, 2006 the company held cash, cash equivalents and short-term investments of $77.2 million.

The company reported that its net loss for the first quarter of 2006 was $9.0 million, as compared to $9.9 million for the first quarter of last year. The decrease in the net loss was principally due to a decrease in research and development expenditures and an increase in net interest income, offset in part by an increase in general and administrative expenses.

Basic and diluted net loss per share was $0.30 for the first quarter of 2006 as compared to $0.40 for the first quarter of 2005. This reduction in net loss per share resulted from a $0.9 million decrease in net loss and a 5.1 million increase in the number of weighted-average shares of common stock outstanding. The increase in the weighted-average shares outstanding was primarily the result of shares issued in connection with a financing the company completed in August 2005.

Revenue in the first quarter of 2006 was $328,000 as compared to $277,000 in the first quarter of 2005. The increase was the result of additional proceeds received from research activities performed under a materials transfer agreement.

Research and development expense for the first quarter of 2006 was $7.4 million, as compared to $9.2 million during the first quarter of 2005. The decrease of $1.8 million in 2006 was the result of a $1.8 million decrease in expenditures related to the manufacturing of clinical trial material and a decrease of $0.9 million in direct clinical trial expenses associated with the completion of the company's Phase III Veronate and Phase II Aurexis clinical trials in 2005. These decreases were offset in part by a $0.9 million increase in salaries and benefits, stock compensation expense related to the adoption of FASB Statement No. 123®, Share-Based Payments, or SFAS 123®, patent- related legal fees, sponsored research, supplies and depreciation and facility-related expenses.

General and administrative expense increased to $2.8 million in the first quarter of 2006 as compared to $1.5 million for the first quarter of 2005. The increase of $1.3 million was the result of an increase of $0.6 million in corporate consulting, legal and professional fees and insurance expenses, $0.3 million in market research activities, $0.2 million in increased salaries and benefits and $0.2 million in stock compensation expense related to the adoption of SFAS 123®.

During the first quarter of 2006, the company adopted SFAS 123®. Accordingly, the company recorded total stock compensation expense of $0.3 million, or $0.01 per share, in the quarter, of which $0.1 million was recorded as research and development expense and $0.2 million was recorded as general and administrative expense.

2006 Financial Guidance

In connection with the workforce reduction announced April 21, 2006, the company anticipates recording a charge of $1.2 million in the second quarter of 2006 for one-time termination benefits. The company further indicated that these workforce reductions are expected to result in annualized savings of approximately $3.6 million in salaries and benefits. In addition, the company plans to reduce and control other costs and expenditures, such that it anticipates its net cash burn rate will approximate $10.0 to $11.0 million during the second quarter of 2006 and will decrease to an average of approximately $5.0 to $6.0 million per quarter during the second half of the year.

Financial guidance involves a high level of uncertainty and is subject to numerous assumptions and factors. These factors include, but are not limited to, the variability, timing and costs associated with conducting clinical trials, the enrollment rates in such trials, the results of these clinical trials, the time and cost to manufacture related clinical trial materials, the funding requirements of preclinical research programs, the cost of filing, prosecuting and enforcing patents or other intellectual property rights, the level of general and administrative expenses needed to support the company's business strategy and the potential that the company may enter into new licensing agreements or strategic collaborations, or change its business strategy in the future.


Recent Developments

Aurexis

- The company announced that it has received FDA authorization to initiate
a two-dose safety and pharmacokinetic trial of Aurexis, its humanized
monoclonal antibody, in 16 patients with S. aureus bloodstream
infections. Prior clinical trials conducted by the company in this
patient population studied a single administration of Aurexis. Patients
in the trial will be administered two doses of Aurexis, intravenously at
20 mg/kg, at a five day interval and will also receive standard of care
antibiotic therapy. The company expects to begin enrolling patients in
the trial during the third quarter of 2006 and to complete enrollment
around year end.

- The company also reported that in addition to completing the two-dose
safety and pharmacokinetic trial, the FDA will also require the company
to complete additional preclinical toxicological studies to evaluate two
doses of Aurexis in combination with antibiotics. The company plans to
perform these studies in parallel with the two-dose safety and
pharmacokinetic clinical trial.

Veronate

- On April 3, 2006, the company announced that its pivotal Phase III
clinical trial of Veronate for the prevention of hospital-associated
infections in premature, very low birth weight infants failed to meet
its primary endpoint or any predefined secondary endpoints.

- On April 28, 2006, the company reported that it was conducting a number
of analyses related to the Phase III Veronate results, and had assembled
an independent panel of experts in the fields of neonatology, immunology
and infectious diseases to review the Veronate program in its entirety.
The company plans to convene the panel in May and intends to complete
its review of the Phase III Veronate results near the end of June 2006.

- The company also reported on April 28, 2006 that it had halted the
manufacture of its current donor-selected immune globulin form of
Veronate. As a result, the company terminated its contract
manufacturing relationship with Nabi Biopharmaceuticals and suspended
future collections of plasma used to manufacture Veronate.

Operations

- On April 21, 2006, the company announced that it was reducing its
workforce by up to 35 employees in order to lower its cost structure and
appropriately align the company's operations with its current stage of
development. The workforce reduction was largely focused in areas
associated with the planned commercialization of Veronate. The company
also announced that on April 24, 2006, the compensation committee of its
board of directors approved an incentive program designed to retain key
executives and employees of the company.

Conference Call and Webcast Information
William D. Johnston, Ph.D., president and chief executive officer, and other members of the Inhibitex senior management team will review first quarter results and provide a general update on the Company via a webcast and conference call today at 8:30 a.m. ET. To access the call, please dial 866- 713-8565 (domestic) or 617-597-5324 (international) five minutes prior to the start time, and provide the access code 45026871. A replay of the call will be available from 10:30 a.m. ET on May 5, 2006 until June 5, 2006 at midnight. To access the replay, please call 888-286-8010 (domestic) or 617-801-6888 (international) and reference access code 98914064. A live audio webcast of the call will also be available on the "Investors" section of the company's website, www.inhibitex.com. An archived webcast will be available in the "Investors" section of the Inhibitex website approximately two hours after the event for a period of thirty (30) days.

About Inhibitex

Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company focused on the discovery, development and commercialization of antibody-based products for the prevention and treatment of serious, life-threatening infections. All of the company's drug development programs are based on its proprietary MSCRAMM protein platform. MSCRAMM proteins are located on the surface of pathogenic organisms, and are responsible for the initiation and spread of infections. The company's most advanced product candidates are Veronate and Aurexis, for which the company has retained all worldwide rights. The company's preclinical programs include a collaboration and joint development agreement with Dyax to develop fully human monoclonal antibodies against MSCRAMM proteins on enterococci and a partnership with Wyeth to develop staphylococcal vaccines. For additional information about the company, please visit www.inhibitex.com.

Inhibitex®, MSCRAMM®, Veronate®, and Aurexis® are registered trademarks of Inhibitex, Inc.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts included in this press release, including statements regarding: the commencement and timing of a planned safety and pharmacokinetic trial and preclinical toxicological studies of a two-dose regimen of Aurexis; estimated net cash burn rate for the second quarter and the remainder of 2006; the estimated charge related to one-time termination benefits; the estimated annualized savings related to recent workforce reductions; expending additional resources on its preclinical and clinical MSCRAMM-based programs; the consideration of other strategic pathways; the company's intent to complete analyses, convene a panel in May and complete its review of the Phase III Veronate results near the end of June 2006; and, the company's plan to halt manufacturing of its current form of Veronate are forward-looking statements. These plans, intentions, expectations or estimates may not actually be achieved and various important factors could cause actual results or events to differ materially from the forward-looking statements that the company makes, including risks related to the outcome of the company's ongoing analyses of the Phase III Veronate trial results; the ability of its expert panel to perform a meaningful assessment of the Veronate program on a timely basis; the ability to recruit clinical trial sites to participate in and the cost and time for investigators to enroll patients in the company's clinical trials; the use of third-party contract clinical research organizations, raw material suppliers and manufacturers, who may not fulfill their contractual obligations or otherwise perform satisfactorily in the future; maintaining sufficient quantities of clinical trial materials on hand to complete its clinical trials; the ability to obtain DSMB or regulatory approval to commence or continue its clinical trials on a timely basis, if at all or in a manner currently anticipated by the company; obtaining, maintaining and protecting the intellectual property incorporated into and supporting its product candidates; maintaining expenses and other cash expenditures substantially in line with planned or anticipated amounts; and cautionary statements contained elsewhere herein and in risk factors described in or referred to in greater detail in the "Risk Factors" section of the company's Annual Report on Form 10-K for the year ended December 31, 2005 as filed with the Securities and Exchange Commission, or SEC, on March 13, 2006. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release.

There may be events in the future that the company is unable to predict accurately, or over which it has no control. The company's business, financial condition, results of operations, and prospects may change. The company may not update these forward-looking statements, even though its situation may change in the future, unless it has obligations under the Federal securities laws to update and disclose material developments related to previously disclosed information. The company qualifies all of the information contained in this press release, and particularly its forward- looking statements, by these cautionary statements.


CONTACTS:
Inhibitex, Inc.
Russell H. Plumb
Chief Financial Officer
[phone]
[e-mail]

Laura Perry (Investors)
Stern Investor Relations, Inc.
[phone]
[e-mail]



INHIBITEX, INC.
(A DEVELOPMENT STAGE COMPANY)
CONDENSED BALANCE SHEETS
(unaudited)

March 31, December 31,
2006 2005
ASSETS
Current assets:
Cash and cash equivalents $33,722,314 $33,842,937
Short-term investments 43,446,875 53,288,016
Prepaid expenses and other current assets 1,486,252 1,917,436
Accounts receivable 283,428 44,923
Total current assets 78,938,869 89,093,312
Property and equipment, net 7,912,088 8,175,074
Total assets $86,850,957 $97,268,386

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $2,524,706 $1,879,191
Accrued expenses 3,632,476 5,316,906
Current portion of notes payable 1,111,111 1,319,445
Current portion of capital lease obligations 857,154 869,043
Current portion of deferred revenue 191,666 191,667
Other current liabilities 1,152,751 1,152,702
Total current liabilities 9,469,864 10,728,954
Long-term liabilities:
Notes payable, net of current portion 1,250,000 1,458,333
Capital lease obligations,
net of current portion 1,434,492 1,646,323
Deferred revenue, net of current portion 650,000 687,500
Other liabilities, net of current portion 1,255,890 1,294,210
Total long-term liabilities 4,590,382 5,086,366
Stockholders' equity:
Preferred stock, $.001 par value; 5,000,000
shares authorized at March 31, 2006 and
December 31, 2005; none issued and outstanding - -
Common stock, $.001 par value; 75,000,000
shares authorized at March 31, 2006 and
December 31, 2005; 30,243,262 and 30,219,715
shares issued and outstanding at March 31,
2006 and December 31, 2005, respectively 30,243 30,220
Common stock warrants 11,514,793 11,514,793
Additional paid-in capital 211,757,981 212,210,931
Deferred stock compensation - (772,347)
Deficit accumulated during the
development stage (150,512,306) (141,530,531)
Total stockholders' equity 72,790,711 81,453,066
Total liabilities and
stockholders' equity $86,850,957 $97,268,386



INHIBITEX, INC.
(A DEVELOPMENT STAGE COMPANY)
CONDENSED STATEMENTS OF OPERATIONS
(unaudited)

Three Months Ended
March 31,
2006 2005
Revenue:
License fees and milestones $37,500 $37,500
Collaborative research and development 125,000 125,000
Grants and other revenue 165,387 114,631
Total revenue 327,887 277,131
Operating expense:
Research and development 7,426,552 9,187,792
General and administrative 2,766,453 1,474,424
Total operating expense 10,193,005 10,662,216
Loss from operations (9,865,118) (10,385,085)
Other income 58,460 -
Interest income, net 824,883 442,397
Net loss (8,981,775) (9,942,688)

Basic and diluted net loss per share $(0.30) $(0.40)

Weighted average shares used to
compute basic and diluted net loss
per share 30,233,142 25,147,579




--------------------------------------------------------------------------------
Source: Inhibitex, Inc.

[bioperformer]

...also da sind sogar die Amis von den Zahlen angetan und greifen sich wieder erste Positionen..

[bioperformer]

...US-Party ist eröffnet....RT:2,17

[bioperformer]

Ziemlich viel Zirkus wird seit gestern im Yahoo-Board zum Thema "Neuzugang zum Nasdaq Biotech-Index" veranstaltet....

Es ist schon sehenswert mit welchen kleinen und großen Mauscheleien da in diesem Board gearbeitet wird - Spezialisten posten da beispielsweise die Originalliste, lassen jedoch mal einfach INHX als 15ten Neuzugang weg, schreiben schon mal prophylaktisch dazu man hoffe, daß bei der Datenübertragung des Postings technisch alles einwandfrei über die Bühne ging - und für "Übertragungsfehler" könne man ja schließlich nichts...

Wie´s der Zufall halt mal nun so wollte fehlt ausgerechnet in der Mitte der Liste genau jede Info zu INHX - welch zufälliges technische Problem ausgerechnet an dieser Stelle...

Absichtliche Falschinformation, wie in diesem gesehenen Beispiel ist bei uns hingegen fast so gut wie ausgeschlossen da leicht nachvollziehbar - in den Staaten hingegen erscheint die SEC eher als zahnloser Tiger in dieser Hinsicht....schade eigentlich, denn wenn etwas so offensichtlich auf der Hand liegt wäre es ein Leichtes derartigen Kandidaten mal ordentlich eines auf die Mütze zu geben..

Wenn jetzt hierzulande auch jemand dadurch Bedenken haben sollte kann man sich unter nachfolgenden Links doch auch selbst vom tatsächlichen Sachverhalt überzeugen und die Kandidatenliste mal genauer in Augenschein nehmen.

http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=…" target="_blank" rel="nofollow ugc noopener">http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=…


http://www.marketwatch.com/News/Story/Story.aspx?guid=%7B89A…" target="_blank" rel="nofollow ugc noopener">http://www.marketwatch.com/News/Story/Story.aspx?guid=%7B89A…


...also nicht aus der Ruhe bringen lassen...

[bioperformer]

gestern veröffentlichte Käufe von Institutionellen Anlegern - insgesamt haben die für $ 4,2 Millionen eingekauft, aber seht selbst anhand der "Einkaufsliste"...


The reported share amounts for QVT Financial, QVT Financial GP LLC, the Fund and QVT Associates GP LLC reflect amounts as of June 7, 2006. The Fund and Separate Account effected the following transactions in the Common Stock during the past 60 days:



• The Fund purchased 7,625 shares of Common Stock, and the Separate Account purchased 1,275 shares of Common Stock in the open market on June 7, 2006 at a price of $1.949 per share. (8.900 shares)

• The Fund purchased 1,885 shares of Common Stock, and the Separate Account purchased 315 shares of Common Stock in the open market on June 6, 2006 at a price of $1.949 per share. (2.200 shares)

• The Fund purchased 12,305 shares of Common Stock, and the Separate Account purchased 2,058 shares of Common Stock in the open market on June 5, 2006 at a price of $1.952 per share. (14.363 shares)

• The Fund purchased 19,104 shares of Common Stock, and the Separate Account purchased 3,196 shares of Common Stock in the open market on June 2, 2006 at a price of $1.919 per share. (22.300 shares)

• The Fund purchased 16,106 shares of Common Stock, and the Separate Account purchased 2,694 shares of Common Stock in the open market on June 1, 2006 at a price of $1.908 per share. (18.800 shares)

• The Fund purchased 3,513 shares of Common Stock, and the Separate Account purchased 587 shares of Common Stock in the open market on May 30, 2006 at a price of $1.980 per share. (4.100 shares)

• The Fund purchased 4,198 shares of Common Stock, and the Separate Account purchased 702 shares of Common Stock in the open market on May 25, 2006 at a price of $1.961 per share. (4.900 shares)

• The Fund purchased 30,926 shares of Common Stock, and the Separate Account purchased 5,174 shares of Common Stock in the open market on May 22, 2006 at a price of $1.889 per share. (36.100 shares)

• The Fund purchased 24,587 shares of Common Stock, and the Separate Account purchased 4,113 shares of Common Stock in the open market on May 19, 2006 at a price of $1.929 per share. (28.700 shares)

• The Fund purchased 21,845 shares of Common Stock, and the Separate Account purchased 3,655 shares of Common Stock in the open market on May 18, 2006 at a price of $1.931 per share. (25.500 shares)

• The Fund purchased 514 shares of Common Stock, and the Separate Account purchased 86 shares of Common Stock in the open market on May 17, 2006 at a price of $1.957 per share. ( 600 shares)

• The Fund purchased 10,452 shares of Common Stock, and the Separate Account purchased 1,748 shares of Common Stock in the open market on May 16, 2006 at a price of $1.997 per share. (12.200 shares)

• The Fund purchased 12,850 shares of Common Stock, and the Separate Account purchased 2,150 shares of Common Stock in the open market on May 15, 2006 at a price of $2.014 per share. (15.000 shares)

• The Fund purchased 22,616 shares of Common Stock, and the Separate Account purchased 3,784 shares of Common Stock in the open market on May 12, 2006 at a price of $1.988 per share. (26.400 shares)

• The Fund purchased 79,927 shares of Common Stock, and the Separate Account purchased 13,373 shares of Common Stock in the open market on May 11, 2006 at a price of $1.992 per share. (93.300 shares)

• The Fund purchased 14,050 shares of Common Stock, and the Separate Account purchased 2,350 shares of Common Stock in the open market on May 9, 2006 at a price of $2.131 per share. (16.400 shares)

• The Fund purchased 5,226 shares of Common Stock, and the Separate Account purchased 874 shares of Common Stock in the open market on May 8, 2006 at a price of $2.123 per share. (6.100 shares)

• The Fund purchased 39,578 shares of Common Stock, and the Separate Account purchased 6,622 shares of Common Stock in the open market on May 5, 2006 at a price of $2.091 per share. (46.200 shares)

• The Fund purchased 11,651 shares of Common Stock, and the Separate Account purchased 1,949 shares of Common Stock in the open market on May 4, 2006 at a price of $2.033 per share. (13.600 shares)

• The Fund purchased 29,957 shares of Common Stock, and the Separate Account purchased 5,143 shares of Common Stock in the open market on May 3, 2006 at a price of $2.019 per share. (35.100 shares)

• The Fund purchased 15,021 shares of Common Stock, and the Separate Account purchased 2,579 shares of Common Stock in the open market on April 28, 2006 at a price of $2.009 per share. (17.600 shares)

• The Fund purchased 24,921 shares of Common Stock, and the Separate Account purchased 4,279 shares of Common Stock in the open market on April 24, 2006 at a price of $2.029 per share. (29.200 shares)

• The Fund purchased 28,335 shares of Common Stock, and the Separate Account purchased 4,865 shares of Common Stock in the open market on April 21, 2006 at a price of $2.005 per share. (33.200 shares)

• The Fund purchased 40,369 shares of Common Stock, and the Separate Account purchased 6,931 shares of Common Stock in the open market on April 20, 2006 at a price of $2.061 per share. (47.300 shares)

• The Fund purchased 15,875 shares of Common Stock, and the Separate Account purchased 2,725 shares of Common Stock in the open market on April 19, 2006 at a price of $1.999 per share. (18.600 shares)

• The Fund purchased 33,553 shares of Common Stock, and the Separate Account purchased 6,347 shares of Common Stock in the open market on April 13, 2006 at a price of $2.013 per share. (39.900 shares)

• The Fund purchased 177,353 shares of Common Stock, and the Separate Account purchased 33,547 shares of Common Stock in the open market on April 12, 2006 at a price of $1.997 per share. (210.900 shares)

• The Fund purchased 97,969 shares of Common Stock, and the Separate Account purchased 18,531 shares of Common Stock in the open market on April 11, 2006 at a price of $2.059 per share. (116.500 shares)

• The Fund purchased 21,528 shares of Common Stock, and the Separate Account purchased 4,072 shares of Common Stock in the open market on April 10, 2006 at a price of $2.183 per share. (25.600 shares)

• On April 4, 2006, the Fund made the following purchases in the open market: 42,046 shares of Common Stock at a price of $2.710 per share; 126,140 shares of Common Stock at a price of $2.740 per share; 42,047 shares of Common Stock at a price of $2.740 per share; 105,116 shares of Common Stock at a price of $2.634 per share; and 389,099 shares of Common Stock at a price of $2.681 per share. (704.448 shares)


• On April 4, 2006, the Separate Account made the following purchases in the open market: 7,954 shares of Common Stock at a price of $2.710 per share; 23,860 shares of Common Stock at a price of $2.740 per share; 7,953 shares of Common Stock at a price of $2.740 per share; 19,884 shares of Common Stock at a price of $2.634 per share; and 73,601 shares of Common Stock at a price of $2.681 per share. (133.252 shares)

[bioperformer]

auch hier noch der link zu dem gestern nach Börsenschluß in USA veröffentlichten Bericht über die enormen Käufe des Funds:

http://secfilings.nasdaq.com/filingFrameset.asp?FileName=000…